RSS
23 Mar 2021

Precigen Announces First Patient Dosed for PRGN-2012 AdenoVerseā„¢ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP)

Author: admintech | Filed under: Press Release

GERMANTOWN, Md., March 23, 2021 /PRNewswire/ — Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the first patient has been dosed in the Phase I study of PRGN-2012, a…